Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.

Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, Fulton A.

Breast Cancer Res Treat. 2014 Jan;143(1):19-31. doi: 10.1007/s10549-013-2779-4. Epub 2013 Nov 27.

2.

Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.

Majumder M, Xin X, Liu L, Girish GV, Lala PK.

Cancer Sci. 2014 Sep;105(9):1142-51. doi: 10.1111/cas.12475. Epub 2014 Sep 11.

3.

COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.

Majumder M, Landman E, Liu L, Hess D, Lala PK.

Mol Cancer Res. 2015 Jun;13(6):1022-33. doi: 10.1158/1541-7786.MCR-14-0543. Epub 2015 Mar 2.

4.

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.

Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK.

Lab Invest. 2012 Aug;92(8):1115-28. doi: 10.1038/labinvest.2012.90. Epub 2012 May 28.

5.

Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.

Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C.

Exp Cell Res. 2003 Oct 1;289(2):265-74.

PMID:
14499627
6.

Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.

Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM.

Breast Cancer Res Treat. 2012 Apr;132(3):1001-8. doi: 10.1007/s10549-011-1675-z. Epub 2011 Jul 15.

7.

Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis.

Li Y, Reader JC, Ma X, Kundu N, Kochel T, Fulton AM.

Breast Cancer Res Treat. 2015 Jan;149(2):403-15. doi: 10.1007/s10549-014-3229-7. Epub 2014 Dec 24.

PMID:
25537642
8.

Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.

Chen JY, Li CF, Kuo CC, Tsai KK, Hou MF, Hung WC.

Breast Cancer Res. 2014 Jul 25;16(4):410. doi: 10.1186/s13058-014-0410-1.

9.

Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.

Wang D, Fu L, Sun H, Guo L, DuBois RN.

Gastroenterology. 2015 Dec;149(7):1884-1895.e4. doi: 10.1053/j.gastro.2015.07.064. Epub 2015 Aug 7.

PMID:
26261008
10.

Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.

Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M.

J Exp Ther Oncol. 2008;7(4):299-312.

PMID:
19227010
11.

Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.

Leth-Larsen R, Terp MG, Christensen AG, Elias D, Kühlwein T, Jensen ON, Petersen OW, Ditzel HJ.

Mol Med. 2012 Sep 25;18:1109-21. doi: 10.2119/molmed.2012.00091.

12.

Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.

Ma X, Kundu N, Rifat S, Walser T, Fulton AM.

Cancer Res. 2006 Mar 15;66(6):2923-7.

13.

Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.

Wahler J, So JY, Cheng LC, Maehr H, Uskokovic M, Suh N.

J Steroid Biochem Mol Biol. 2015 Apr;148:148-55. doi: 10.1016/j.jsbmb.2014.10.016. Epub 2014 Oct 31.

14.

Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.

Rappa G, Lorico A.

Exp Cell Res. 2010 May 15;316(9):1576-86. doi: 10.1016/j.yexcr.2010.01.012. Epub 2010 Jan 11.

15.

Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.

Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, Zhang M.

PLoS One. 2012;7(9):e46342. doi: 10.1371/journal.pone.0046342. Epub 2012 Sep 28.

16.

Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.

Holt DM, Ma X, Kundu N, Collin PD, Fulton AM.

J Immunother. 2012 Feb-Mar;35(2):179-88. doi: 10.1097/CJI.0b013e318247a5e9.

17.

High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.

Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL.

J Cell Mol Med. 2009 Aug;13(8B):2236-52. doi: 10.1111/j.1582-4934.2008.00455.x. Epub 2008 Aug 4.

18.

ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F, Ansieau S.

Mol Cancer. 2014 Sep 12;13:213. doi: 10.1186/1476-4598-13-213.

19.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.

Hum Pathol. 2012 Mar;43(3):364-73. doi: 10.1016/j.humpath.2011.05.005. Epub 2011 Aug 10.

PMID:
21835433
20.

P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.

Vieira AF, Ricardo S, Ablett MP, Dionísio MR, Mendes N, Albergaria A, Farnie G, Gerhard R, Cameselle-Teijeiro JF, Seruca R, Schmitt F, Clarke RB, Paredes J.

Stem Cells. 2012 May;30(5):854-64. doi: 10.1002/stem.1075.

Items per page

Supplemental Content

Write to the Help Desk